Gabapentin Tablet
Product Images NDC 68788-8790

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-8790). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Tablets 800mg Cv (800 mg 500s)

Label for Gabapentin Tablets 800 mg, oral dosage form, from Preferred Pharmaceuticals Inc. The label indicates the product is a generic for Neurontin containing 800 mg gabapentin per tablet. Storage instructions and a caution regarding federal law prohibiting drug transfer are included. The label has text in English and Spanish for usage directions.*

FDA Label Image

Clcr (Equation)

A formula for calculating creatinine clearance (CLCr) based on age, weight, serum creatinine levels, and a gender adjustment factor. It is presented as a mathematical expression involving these variables.*

FDA Label Image

Figure-1 (Figure1)

A line chart titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' showing mean pain scores over 8 weeks. The x-axis represents weeks including a baseline, with a 4-week dose titration period followed by a 4-week fixed dose period. The y-axis measures mean pain scores from 0 to 10. Two lines are shown: one for placebo maintaining steady scores around 6.5, and one for Gabapentin 3600 mg/day showing a decreasing trend from approximately 6 to around 4.*

FDA Label Image

Figure-2 (Figure2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over 7 weeks. The x-axis represents weeks from baseline to week 7, and the y-axis represents mean pain scores from 0 to 10. Three lines are plotted comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The plot highlights a 3-week dose titration period followed by a 4-week fixed dose period, with pain scores decreasing more for Gabapentin treatments than placebo.*

FDA Label Image

Figure-3 (Figure3)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) with different doses of gabapentin (GBP) in two studies. The chart shows response proportions for placebo and gabapentin doses 1800 mg, 2400 mg, and 3600 mg, with gabapentin groups having higher response rates. Statistical significance is noted for some bars.*

FDA Label Image

Figure-4 (Figure4)

A scatter plot chart illustrating responder rate differences from placebo in patients aged 12 years or older receiving Gabapentin as adjunctive therapy for partial seizures. The x-axis represents daily Gabapentin dose in mg (600, 900, 1200, 1800), and the y-axis shows the percentage difference in responder rate. Three studies labeled a, b, and c are depicted with distinct markers at different doses.*

FDA Label Image

Struc (Struct)

Chemical structure diagram of the active ingredient Gabapentin, showing its cyclohexane backbone with attached amine (CH2NH2) and carboxyl (CH2CO2H) functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.